Back ستيوارت شرايبر Arabic ستيوارت شرايبر ARZ استوارت شریبر AZB Stuart Schreiber German استوارت شریبر Persian Stuart L. Schreiber French スチュアート・シュライバー Japanese Шрайбер, Стюарт Russian Stuart Schreiber Turkish Стюарт Шрайбер Ukrainian
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Stuart L. Schreiber | |
|---|---|
 | |
| Born | February 6, 1956 |
| Alma mater | University of Virginia Harvard University |
| Known for | Organic Synthesis Chemical Biology Human Biology Therapeutics Discovery |
| Awards | Arthur C. Cope Award (2015) Wolf Prize (2016) |
| Scientific career | |
| Fields | Chemical Biology |
| Institutions | Yale University Harvard University Broad Institute |
| Thesis | I: Oxidation of tertiary amines / II: Peroxides in organic synthesis (1981) |
| Doctoral advisor | Robert Burns Woodward Yoshito Kishi |
Stuart Schreiber is an American chemist who is the Morris Loeb Research Professor at Harvard University,[1] a co-Founder of the Broad Institute,[2] Howard Hughes Medical Institute Investigator, Emeritus,[3] and a member of the National Academy of Sciences[4] and National Academy of Medicine.[5] He currently leads Arena BioWorks.
His work integrates chemical biology and human biology to advance the science of therapeutics. Key advances include the discovery that small molecules can function as “molecular glues” that promote protein–protein interactions, the co-discovery of mTOR and its role in nutrient-response signaling, the discovery of histone deacetylases and (with Michael Grunstein and David Allis) the demonstration that chromatin marks regulate gene expression, the development and application of diversity-oriented synthesis to microbial therapeutics, and the discovery of vulnerabilities of cancer cells linked to genetic, lineage and cell-state features, including ferroptotic vulnerabilities. His awards include the Wolf Prize in Chemistry and the Arthur Cope Award. His approach to discovering new therapeutics guided many biotechnology companies that he founded, including Vertex Pharmaceuticals and Ariad Pharmaceuticals. He has founded or co-founded 14 biotechnology companies, which have developed 16 first-in-human approved drugs or advanced clinical candidates.
- ^ "Stuart L. Schreiber". chemistry.harvard.edu. Retrieved 2023-11-29.
- ^ "Stuart L. Schreiber". Broad Institute. 2015-11-23. Retrieved 2023-11-29.
- ^ "Stuart L. Schreiber, PhD | Investigator Emeriti Profile | 1994-2018 | HHMI". www.hhmi.org. Retrieved 2023-11-29.
- ^ "Stuart L. Schreiber". www.nasonline.org. Retrieved 2023-11-29.
- ^ "The National Academy of Medicine honors Stuart Schreiber". chemistry.harvard.edu. Retrieved 2023-11-29.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search